WS #16029
Amidst broader market weakness, specific sectors are showing resilience driven by strong fundamentals. Alcoa shares surged 7% after reporting third-quarter profits that beat forecasts and demonstrated impressive cash generation, benefiting from tight aluminum supply. In biotech, ImmunityBio announced robust Phase 3 data for its ANKTIVA treatment, showing an 84% cystectomy avoidance rate at three years. These earnings highlights suggest that companies with tangible products and pricing power are outperforming speculative growth names.
Industrial and Biotech Earnings
Amidst broader market weakness, specific sectors are showing resilience driven by strong fundamentals. Alcoa shares surged 7% after reporting third-quarter profits that beat forecasts and demonstrated impressive cash generation, benefiting from tight aluminum supply. In biotech, ImmunityBio announced robust Phase 3 data for its ANKTIVA treatment, showing an 84% cystectomy avoidance rate at three years. These earnings highlights suggest that companies with tangible products and pricing power are outperforming speculative growth names.